Zhang J, Zhang Y, Wu D, et al. - Researchers examined the clinical experience with isavuconazole, which is a broad‐spectrum triazole for the treatment of invasive fungal disease (IFD), in Chinese individuals. Participants were Chinese healthy volunteers who participated in a phase I pharmacokinetics and safety study of single/multiple doses of isavuconazole (n = 36) and Chinese patients who participated in the global Phase III SECURE study that evaluated safety and efficacy of isavuconazole vs voriconazole for IFD treatment (n = 26). Findings suggest a favorable risk–benefit profile of isavuconazole in Chinese patients although there is necessity for further research. Isavuconazole was reported to be linked with reduced incidence of hepatobiliary, eye, skin, subcutaneous tissue and psychiatric disorders compared with voriconazole and lower incidence of treatment‐related treatment‐emergent adverse events (TEAEs), serious TEAES or death overall.